Private Hospital Site Assessment
A prime London private hospital development was left in limbo following the administration of its original operator, leaving an investor with a stalled asset and critical decisions to make. CF was brought in to conduct rapid commercial due diligence, applying specialist health sector expertise to assess whether reconfiguring the estate as a single-theatre, high-throughput day-case model was operationally and clinically feasible within the site’s physical constraints. We delivered a rigorous assessment of market demand, the competitive landscape, and valuation assumptions — ultimately informing the investor’s decision on whether to proceed with further investment and which acquisition strategy, leasehold or freehold, represented the stronger path forward.
What was the challenge?
CF was commissioned by an investor to undertake rapid commercial due diligence on a private hospital development in a prime London location, which had paused following the administration of the original operator.
The core task was to determine whether reconfiguring the estate to a single‑theatre, high‑throughput day‑case model was operationally and clinically feasible within the physical constraints (recovery capacity, small basement theatre, patient flow/zoning), and commercially credible against market demand, competition, and valuation assumptions informing whether further investment and a leasehold vs freehold strategy should proceed.
What did we do?
We approached the work as an integrated clinical‑operational and commercial assessment, starting with a practical, on‑the‑ground review of the estate to test whether the proposed configuration could run safely and efficiently (patient flow, recovery capacity, theatre size, lift/trolley constraints, zoning and infection‑control considerations, and alignment to Hospital Building Note expectations).
High-volume activity for the selected procedures is concentrated in London, with several leading hospitals located near the hospital site
| Hospital | Activity |
|---|---|
| Kingston Hospital | 875 |
| Ealing Hospital | 715 |
| St Thomas' Hospital | 670 |
| Croydon University Hospital | 565 |
| St George's Hospital | 540 |
| The Clementine Churchill Hospital | 530 |
| St Mary's Hospital | 455 |
| Spire London East | 435 |
| The London Independent Hospital | 425 |
| Princess Royal University Hospital | 410 |
| Chelsea & Westminster Hospital | 405 |
| The Sloane Hospital | 395 |
| Charing Cross Hospital | 390 |
| Royal Free Hospital | 370 |
| Homerton University Hospital | 370 |
- Activity includes both self-pay and NHS-funded procedures. Private medical insurance is excluded due to data limitations.
- All hospitals with the highest activity and closest proximity to the hospital offer all four selected procedures.
Activity delivered by local NHS hospital sites in NCL grew 14% annually, with growth across all procedure types
- In 2024/25, 2,227 procedures were delivered at NHS hospitals in North Central London.
- Activity for the four identified procedures increased by 14% year-on-year, highlighting growing demand.
- Most of the activity was for hernia repair and carpal tunnel.
- Due to data limitations, it is not possible to review waiting list data for the identified procedures.
In parallel, we interrogated the operator’s proposition and the implied valuation story by triangulating market demand and competitive positioning using procedure‑level activity intelligence (e.g., PHIN and NHS datasets), mapping nearby providers within a tight local radius, and benchmarking what comparable sites actually deliver.
We then stress‑tested the business plan by translating turnover ambitions into the required annual case volumes and day‑by‑day throughput and assessing whether those volumes were plausible given the site’s clinical scope (likely limited to local anaesthetic/sedation in this footprint), the absence of on‑site diagnostics/outpatients, and the intensity of local competition.
Crucially, we framed our conclusions as a “what needs to be true” investment test, linking operational realities to the EBITDA/valuation assumptions and identifying the specific constraints and mitigations that would determine success or failure.
What differentiates CF is this ability to fuse senior clinical judgement with hard‑edged investment analytics at pace: we don’t just comment on a layout or a market in isolation, we connect estate feasibility, regulatory/clinical practicality, demand dynamics and financial deliverability into a single, actionable view that a lender can use to underwrite (or avoid) further capital commitment.
How did we do it?
What was the impact?
The work delivered value across several interconnected dimensions, translating a complex and uncertain situation into a clear, evidence-based investment view.
By aligning quickly with the investor on the core decision questions, we produced an executive-grade assessment of viability that enabled a confident “proceed / pause / conditions” pathway. Central to this was surfacing the true gating issues within the estate — from patient flow and recovery capacity to theatre constraints and lift/trolley practicality — focusing attention on what really determines success rather than secondary concerns.
On the commercial side, CF turned the operator’s revenue ambitions into hard numbers, translating targets into required throughput and annual volumes and benchmarking these against real-world comparators. This gave the investor a robust evidence base to challenge assumptions and negotiate with confidence. Alongside this, we defined a credible clinical offer for the site — validating that it can safely deliver low-complexity day cases under local anaesthetic or sedation — aligning the service model to the building’s physical realities and materially reducing delivery risk.
The market case was tested with equal rigour through:
- Demand trend analysis combined with close-radius competitor mapping
- Assessment of differentiation constraints, notably the absence of on-site diagnostics and outpatient facilities
- Clarity on what would be required to win and sustain patient volume in a competitive London market
Finally, CF linked operational deliverability directly to the valuation logic through a “what needs to be true” framework, outlining pragmatic alternative configurations and pathways that strengthened downside protection and preserved strategic flexibility for the investor.
Client Testimonial
